Market Cap 4.76M
Revenue (ttm) 0.00
Net Income (ttm) -11.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 58,280
Avg Vol 967,948
Day's Range N/A - N/A
Shares Out 2.27M
Stochastic %K 13%
Beta 1.14
Analysts Sell
Price Target $25.00

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 776 3133
Fax: 443 288 4420
Address:
7380 Coca Cola Drive, Suite 106, Hanover, United States
TheDrunkTrader69
TheDrunkTrader69 Feb. 23 at 10:23 PM
$PCSA Not advice, but im in it until the end either get a good price to sell or lose it all. Holding for dear life, other stocks are sucking just as bad so either way screwed lol. Its only money
0 · Reply
maniamedmao
maniamedmao Feb. 23 at 7:14 PM
$PCSA I didn’t come here for months and I still see people having hope while you can just see that the whole market has dropped for the last few months even index funds are down ! So no news will brings this up unless the market decide to
0 · Reply
__ChartMenace
__ChartMenace Feb. 23 at 12:21 PM
0 · Reply
Jwa68
Jwa68 Feb. 21 at 10:42 PM
$PCSA Just in case anyone is keeping score...down 99.89%.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 11:20 PM
$PCSA RSI: 27.04, MACD: -0.3830 Vol: 0.41, MA20: 2.56, MA50: 3.41 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 20 at 9:50 PM
$PCSA To me all that this last contract expiring news just means we know have 2 great drugs ready to explode any day, new partnership opportunities and growthbin the near future. Im watching very closely
0 · Reply
Jwa68
Jwa68 Feb. 20 at 3:32 PM
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 20 at 1:55 PM
0 · Reply
Jwa68
Jwa68 Feb. 19 at 11:36 PM
$PCSA Since they announced entering into the license transaction option in a press release, do they now equally have a responsibility to shareholders and the SEC, to anounce the termination in the same manner? Why just an 8k? Item 1.02 Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
1 · Reply
Jwa68
Jwa68 Feb. 19 at 10:33 PM
$PCSA Shameful. Either you are incredibly niave and unlucky, or you were complicit. Regardless, you sure hurt a lot of people my friend as have your friends in management. Item 1.02 Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
0 · Reply
Latest News on PCSA
Processa Pharmaceuticals Provides Portfolio and Business Update

Jul 1, 2025, 9:00 AM EDT - 8 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update


TheDrunkTrader69
TheDrunkTrader69 Feb. 23 at 10:23 PM
$PCSA Not advice, but im in it until the end either get a good price to sell or lose it all. Holding for dear life, other stocks are sucking just as bad so either way screwed lol. Its only money
0 · Reply
maniamedmao
maniamedmao Feb. 23 at 7:14 PM
$PCSA I didn’t come here for months and I still see people having hope while you can just see that the whole market has dropped for the last few months even index funds are down ! So no news will brings this up unless the market decide to
0 · Reply
__ChartMenace
__ChartMenace Feb. 23 at 12:21 PM
0 · Reply
Jwa68
Jwa68 Feb. 21 at 10:42 PM
$PCSA Just in case anyone is keeping score...down 99.89%.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 11:20 PM
$PCSA RSI: 27.04, MACD: -0.3830 Vol: 0.41, MA20: 2.56, MA50: 3.41 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 20 at 9:50 PM
$PCSA To me all that this last contract expiring news just means we know have 2 great drugs ready to explode any day, new partnership opportunities and growthbin the near future. Im watching very closely
0 · Reply
Jwa68
Jwa68 Feb. 20 at 3:32 PM
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 20 at 1:55 PM
0 · Reply
Jwa68
Jwa68 Feb. 19 at 11:36 PM
$PCSA Since they announced entering into the license transaction option in a press release, do they now equally have a responsibility to shareholders and the SEC, to anounce the termination in the same manner? Why just an 8k? Item 1.02 Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
1 · Reply
Jwa68
Jwa68 Feb. 19 at 10:33 PM
$PCSA Shameful. Either you are incredibly niave and unlucky, or you were complicit. Regardless, you sure hurt a lot of people my friend as have your friends in management. Item 1.02 Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
0 · Reply
Jwa68
Jwa68 Feb. 19 at 10:23 PM
$PCSA Even I was hoping I'd be wrong. Based on the past, we all should have known this was coming. Remember the pr and apparent stock promotion where they raised$7M? Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate Download as PDFJune 17, 2025 9:00am EDT $452.5 million in total milestone payments $2.5 million in near-term payments Double-digit royalties on future net product sales Item 1.02 Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
0 · Reply
StanlySmith
StanlySmith Feb. 19 at 9:16 PM
$PCSA 8K out not good me thinks
1 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 5:32 PM
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 18 at 7:51 PM
0 · Reply
BreakoutPika
BreakoutPika Feb. 18 at 12:30 PM
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 6:12 PM
0 · Reply
_PikaPlays
_PikaPlays Feb. 17 at 1:05 PM
0 · Reply
Trex28
Trex28 Feb. 13 at 7:26 PM
$PCSA I just jumped back in today and picked up 15k shares. I’m gambling… but I’m taking the risk they pop up again
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Feb. 11 at 5:26 PM
$PCSA Can you smell it.
2 · Reply
Goldengun23
Goldengun23 Feb. 10 at 1:33 PM
$PCSA any day now with an update on the intact agreement
0 · Reply
Jwa68
Jwa68 Feb. 10 at 5:02 AM
$PCSA We should be hearing imminently if Intact Pharmaceuticals is proceeding with the license or walking away. "The obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet, the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and twenty (120) days for a fee of $30,000. There can be no assurance that the Company and Intact will enter into a license agreement." https://www.processapharmaceuticals.com/news-media/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting
0 · Reply
Jwa68
Jwa68 Feb. 10 at 4:55 AM
$PCSA January 26, 2022...Share price approximately $2000 a share, today $2.26. We believe 2022 will be a transformative year for Processa as our multi-asset pipeline continues to mature and we achieve important clinical milestones." CEO David Young. https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/63/processa-pharmaceuticals-ceo-dr-david-young-issues-letter
0 · Reply